Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2012-01-13 Transaction in Own Shar…
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 100% confidence The document explicitly details the ongoing 'share buy-back programme' initiated by ALK-Abelló A/S. It provides weekly transaction data (number of shares bought back, average price, and amount) related to this program. This activity—the company purchasing its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS.
2012-01-13 English
Director's Dealing 2012
Director's Dealing
2012-01-06 Danish
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 99% confidence The document is titled "Aktietilbagekøbsprogram – meddelelse nr. 8" (Share Buyback Program - Announcement No. 8) and details the weekly transactions made under an ongoing share buyback program initiated on November 15, 2011. It explicitly reports the number of shares repurchased, the average price, and the total amount spent for specific trading days, culminating in an accumulated total. This directly corresponds to the definition of reporting the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category.
2012-01-06 English
Transaction in Own Shares 2011
Transaction in Own Shares Classification · 98% confidence The document is titled "Aktietilbagekøbsprogram – meddelelse nr. 7" (Share Buyback Program - Announcement No. 7) and details the ongoing share repurchase activities of ALK-Abelló A/S, including the number of shares bought, the average price, and the cumulative amount spent. This directly relates to the company managing its own stock, which falls under the category of 'Transaction in Own Shares'. The document is a specific announcement regarding this activity, not a general regulatory filing or a report on other financial aspects.
2011-12-30 English
Transaction in Own Shares 2011
Transaction in Own Shares Classification · 98% confidence The document explicitly details the activity under a 'Share buy-back programme' initiated by ALK-Abelló A/S. It reports the number of shares bought back on specific trading days and the accumulated total. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase activities.
2011-12-30 Danish
Transaction in Own Shares 2011
Transaction in Own Shares Classification · 100% confidence The document explicitly details the ongoing purchase of the company's own shares ('share buy-back programme') and provides a weekly breakdown of the number of shares bought back, the average price, and the total amount transacted in DKK. This activity directly corresponds to the definition of 'Transaction in Own Shares' (POS). The document is a specific report on this activity, not merely an announcement of a report's publication.
2011-12-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.